Kornimate/medical-research-clean huggingface dataset:
regulation of postprandial nitric oxide bioavailability and vascular function by dairy milk

Conditions: Prediabetes

Summary: cardiovascular disease (cvd) is the leading cause of death in the united states. short-term increases in blood sugar, or postprandial hyperglycemia (pph), affect blood vessel function and increase the risk of cvd. greater intakes of dairy foods have been associated with a lower risk of cvd, but whether these effects occur directly or indirectly by displacing foods in the diet that might increase cvd risk is unclear. the health benefits of dairy on heart health are at least partly attributed to its ability to limit pph and resulting pph-mediated responses leading to vascular dysfunction. this provides rationale to further investigate dairy as a dietary strategy to reduce pph and risk for cvd. the objective of this study is to define the extent to which dairy milk, and its whey and casein protein fractions, protect against postprandial vascular dysfunction by reducing oxidative stress responses that limit nitric oxide bioavailability to the vascular endothelium in adults with prediabetes.

this study consists of four, 3-hour postprandial trials in response to consuming the following dietary treatments: 1. oral glucose challenge, 2. oral glucose challenge in combination with non-fat milk, 3. oral glucose challenge in combination with whey protein isolate, and 4. oral glucose challenge in combination with sodium caseinate. for three days preceding each trial, participants will be provided all meals to standardize physiologic responses to test meals. on each trial day, vascular function will be assessed and blood samples collected prior to and at 30 minute intervals for 3 hours following test meal ingestion.

Eligibility criteria:
inclusion criteria: 1. hemoglobin a1c 5.7-6.4% 2. non-dietary supplement user 3. no medications affecting vasodilation, inflammation, or energy metabolism 4. no cvd 5. nonsmokers 6. individuals having blood pressure \<140/90 mmhg and total cholesterol \<240 mg/dl exclusion criteria: 1. unstable weight (±2 kg) 2. vegetarian or dairy allergy 3. alcohol intake \>3 drinks/day or \>10 drinks/week 4. ≥7 hours/week of aerobic activity

Keywords: dairy milk glucose postprandial hyperglycemia prediabetes blood glucose oxidative stress vascular health vascular function
measurements of anemia and physiologic tissue response to blood transfusions in vlbw infants using quantitative nirs

Conditions: Infant Development

Summary: the study quantified functional measures of red blood cell mass and oxygen in neonatal tissues using a non-invasive optical technique: near infrared optical spectroscopy . the study will determine the absolute concentrations of deoxygenated and oxygenated hemoglobin and calculate the tissue hemoglobin saturation and total hemoglobin concentration in viv. near infrared optical spectroscopy technique use to assessing and defining tissue status in the anemic state and the tissue's response to transfusions, as well as in monitoring hemoglobin and hematocrit without pain or loss of blood.

near infrared optical spectroscopy measurements will be conducted on the muscle, on the upper leg,arm or on the back, abdomen and the head. the actual location will depend upon the neonate position and size. a small soft plastic optical fibers probe will be placed to the select study areas and thhe time of the measurement will not exceed 1 hour. nirs measurements of hemoglobin and hemoglobin saturation in tissues before and after red-cell transfusions in vlbw infants will determine the true effect of the transfusions, and develop more substantial guidelines regarding indications for transfusion. the accuracy of conventional (invasive) measurements of hb and hct could be comparison with results from the nirs technique and clinical usefulness of the nirs technique could be evaluated by comparison with trends in conventionally measured values taking fluid status into account. near-infrared light does not ionize biological tissue and poses no significant health risk. since water absorption is low within this spectral range, local heating of the tissue is also minimal. burns and heat damage to the neonate are highly unlikely.

Eligibility criteria:
inclusion criteria: * infants weighing less than 1500 grams at birth * infants receiving at least one packed red blood cell transfusion exclusion criteria: * neonates who are too unstable as determined by the clinicians for additional human contact
"parathyroid tissues anatomic localizations are displaced downward in parathyroid hyperplasia cases"

Conditions: Parathyroid Hyperplasia

Summary: this study investigates if parathyroid tissues anatomic localizations are displaced downward in parathyroid hyperplasia cases or not.

parathyroid tissues gets heavier when they become hyperplasia. because of this weight change, they change their normal anatomic positions. 125 patients who have been operated earlier will be included in the study.

Eligibility criteria:
inclusion criteria: * patients who have undergone an operation due to parathyroid hyperplasia exclusion criteria: -
feasibility of a health care provider guided exercise intervention prior to surgical resection of pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. willingness and ability to participate in the study procedures 2. pathologically confirmed pancreatic cancer 3. candidate for neoadjuvant therapy followed by surgical resection with potentially curative intent. note: there is no limitation on duration of neoadjuvant therapy. 4. planned to have at least 2 weeks after completing the last neoadjuvant therapy and surgery 5. over the age of 18 6. ability to engage in physical activity as determined by physiatrist review after completion of the physical activity readiness questionnaire (par-q) exercise survey and chart review 7. agree to study blood draws and tissue collection exclusion criteria: 1. evidence of metastatic disease 2. inability to complete physical activity due to recent injury or surgery 3. uncontrolled heart disease limiting physical activity 4. participation in another interventional trial that excludes participation in this protocol 5. subjects who anticipate undergoing a procedure during the course of the trial that will render them unable to engage in physical activity for more than 48 hours 6. pregnant subjects 7. individuals who lack the capacity to consent

Keywords: hcp-guided exercise
histamine h2 antagonism as adjuvant therapy in treatment resistant schizophrenia

Conditions: Schizophrenia

Summary: the purpose of the study is to investigate whether blockade of the histamine h2 receptors in the brain will have any beneficial effect on the symptoms of subjects with schizophrenia.

histamine functions as a neurotransmitter in the brain. it has an important role as modulator of the release of other neurotransmitters, including dopamine. the histamine receptors are widely expressed in the brain, h1 and h2 receptors are post-synaptic, h3 a pre-synaptic autoreceptor. there is an abundance of neurobiologic data from animal and human studies supporting the role of histamine in the pathogenesis and treatment of psychoses. in 1990 a case report of a treatment resistant subject with schizophrenia whos symptoms improved markedly when he was prescribed a h2 antagonist because of peptic ulcer. later, a open-label trial including 18 patients has been performed, reporting significant symptom reduction, especially on negative symptoms. also the subjective comments both by the subjects and the investigators in that study were optimistic and suggested an effect primarily on negative symptoms. the present study will be the first double-blind, randomized, placebo controlled, parallel group study of the subject matter. the study focuses on treatment resistant schizophrenia cases in the stable phase.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia assessed by scid-i (dsm-iv) as well as rdc-criteria * patient record mention of schizophrenia (icd-10) at least 5 years previously * disability pension due to psychiatric disorder * at least 3 points on the cgi scale exclusion criteria: * epilepsy or a history of unclear seizures * stroke * parkinson's disease * aids * substance addiction or abuse within 3 months prior to enrolment. * individuals who are deemed at risk for aggressive behavior or suicide by their clinician * pregnant and breast-feeding subjects * serious unstable physical illness * persons who have been deemed legally incapacitated according to finnish law (laki holhoustoimesta 1.4.1999/442, 3. luku, 18 §) * individuals who use h2-antagonists as prescribed by a physician * known allergy to famotidine or any other component of the pepcidin® 40 mg tablet * glomerular filtration rate (gfr) according to the cockcroft-gault formula \< 30 ml/min

Keywords: treatment resistant chronic
ultraviolet light therapy for systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: objectives: i. evaluate the mechanisms of ultraviolet a-1 light therapy in patients with systemic lupus erythematosus and normal controls.

protocol outline: treatment with ultraviolet a-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. the dose and frequency are progressively decreased over the next 9 weeks.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting american rheumatism association criteria and normal controls --prior/concurrent therapy-- no requirement for tetracycline or other photosensitizing drugs

Keywords: arthritis & connective tissue diseases immunologic disorders and infectious disorders rare disease systemic lupus erythematosus
poor quality of life associated with traditional chinese medicine constitution in hiv-infected men who have sex with men

Conditions: HIV Infections; Quality of Life

Summary: this study explores the pathological constitution as it relates to low quality of life with hiv- infected msm patients, as a reference for clinical treatment.

introduction :this study explores the pathological constitution as it relates to low quality of life with hiv- infected msm patients, as a reference for clinical treatment. methods :it has a cross-sectional research design using structured questionnaires to collect data,including patient's basic case data, cd4+, cd4+/cd8+ ratio, wang qi constitution and whoqol-bref -taiwan version questionnaires. we consider the association between the constitutions and quality of life for hiv-infected msm patients.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hiv infected. * age greater than 20 years old (including) and less than 60 years old. * conscious clear and voluntary to attend the project with agreement. * willing to fill out the informed consent form. exclusion criteria: * conscious unclear * patients had histories of severe psychiatric disorders ( ex: schizophrenia) or if they met the criteria of diagnostic and statistical manual of mental disorders ( ex: dementia) * age \< 20 years old. * the patient does not want to fill out the informed consent form for any reason.
chemotherapy plus endostatin in advanced pancreatic neuroendocrine tumor

Conditions: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor

Summary: temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor


Eligibility criteria:
inclusion criteria: 1. 18 years of age and older 2. ecog ≤2 3. pathologically confirmed locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumor. 4. prior treatment with one-line chemotherapy is allowed, with the exception of prior treatment with temozolomide or dacarbazine or endostatin within the past 6 months 5. disease progressed during or after last therapy 6. minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy 7. disease progressed within the past 12 months。 8. patients must have at least one measurable site of disease according to recist1.1 criteria that has not been previously irradiated. 9. adequate bone marrow, liver and renal function 10. life expectancy 3 months or more 11. patient informed consent。 exclusion criteria: 1. concurrent use of octreotide or other drug that may have efficacy in neuroendocrine tumor. 2. 2 or more lines of prior chemotherapy。 3. patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study 4. uncontrolled infectious disease。 5. other malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin 6. uncontrolled brain or leptomeningeal metastases 7. patients with known hypersensitivity to temozolomide or endostatin。 8. patient could not take tablets。

Keywords: temozolomide endostatin advanced well-differentiated pancreatic neuroendocrine tumor
plasma mirnas predict radiosensitivity of different fractionation regimes in palliative radiotherapy for advanced non-small cell lung cancer：multicenter controlled study.(radmir-01)

Conditions: Advanced Nsclc

Summary: lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (nsclc). most of them present with advanced stage at diagnosis. radiotherapy is an important treatment strategy for advanced non-small cell lung cancer. however patients have different responses to radiotherapy due to individual differences, thus there is still lacking of sensitive markers to predict treatment response at present. using bioinformatics to process the data and small sample clinical trial, our previous study found 5 plasma mirnas were related to radiosensitivity. the design is controlled clinical trial. according to the size of lung lesions, the investigators divided the patients into hyperfractionated radiotherapy group（50gy/11f/2w) with lesion ≤5cm in diameter and conventional fractionated radiotherapy group（60gy/30f/6w）with lesion \>5cm in diameter.


Eligibility criteria:
inclusion criteria: 1. pathological histology and/or cytology confirmed nsclc; 2. based on ajcc cancer staging, iiia, iiib, iv lung cancer patients with nsclc; 3. ps 0-2; 4. expected survival \> 3 months; 5. age 18\~75 years old; 6. the function of lung, liver, kidney, bone marrow was normal; 7. the patients had not received radiotherapy for previous primary tumor and metastases; 8. at least accept 2-4 cycles of chemotherapy,not disease progression after chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy; 9. wild-type egfr; 10. sensitive mutant egfr, but refused to targeted therapy; 11. in line with the indications of radiotherapy and accept it; 12. voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent. exclusion criteria: 1. vital organs (e.g., heart, liver, kidney) have serious dysfunction; 2. patients with other malignancies; 3. patients with a history of autoimmune disease; 4. the patients are pregnant and lactating (women of childbearing age need to check the pregnancy test); 5. in the activity of acute or chronic infectious diseases; 6. patients with a clear history of drug allergy or allergic genus; 7. patients with participating in other clinical trials at the same time; 8. other cases that researchers believe that patients should not participate in the present trial.
analysis of single respiratory viral infections versus co-infections: prevalence and icu needs in hospitalized adults

Conditions: Respiratory Tract Infections; Virus Diseases; Coinfection

Summary: the objective of our study is to investigate the prevalence of viral respiratory infections in inpatients following the end of the pandemic. additionally, the prevalence of patients co-infected with multiple viruses simultaneously will be assessed. in the secondary part of the study, the development of respiratory tract infections, the need for intensive care, and mortality rates within seven days will also be evaluated, and risk factors for patients with a more severe clinical course will be statistically calculated.

this study aims to determine the prevalence of viral respiratory agents in hospitalized patients post-covid-19 and to examine the clinical course of respiratory viral co-infections, which are expected to be more severe. this study will be conducted retrospectively at kocaeli university hospital between may 2023, considered the end date of the pandemic, and january 2024. patients over 18 years of age will be included, and data will be accessed through the hospital automation system. patients with sars-cov-2 pcr-positive symptoms and those expected to use molnupiravir due to the need for treatment will be considered as covid-19. respiratory tract agents will be detected by multiplex pcr from symptomatic inpatients. all patients with influenza will also receive oseltamivir. the distribution of viruses, the need for intensive care hospitalization, and whether they cause death within seven days, as well as the prevalence, clinical course, and risk factors of viral co-infections expected to be clinically more severe in the literature, will also be examined

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients admitted to our clinic or consulted to infectious diseases from other inpatient services. * patients diagnosed with upper or lower respiratory tract infections due to viral agents exclusion criteria: * patients infected with bacterial agents will not be included in the study. * patients admitted from the outpatient clinic were not included in the study plan.
laboratory study of early tumor markers in the peripheral blood of glioblastoma multiforme patients

Conditions: Glioblastoma Multiforme; Healthy Volunteers

Summary: the purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.

despite aggressive therapies, glioblastoma multiforme (gbm) is rapidly fatal. gbms are increasingly recognized for occasionally metastasizing through the peripheral blood to distant locations. this research study involves the detection and novel characterization of human gbm (hgbm) circulating tumor cells (ctcs) within the peripheral blood of brain tumor patients by identifying their unique cell surface antigen profile, determining an optimal isolation protocol, and quantitatively and qualitatively reporting the yield and characteristics.

Eligibility criteria:
inclusion criteria: * 18 to 89 years of age * weight of at least 110 pounds * able to provide informed consent for self exclusion criteria: * patients with active malignant tumors other than gbm

Keywords: gbm brain tumor brain neoplasm control normal control volunteer
iph5201 as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to assess the safety and tolerability and to determine the dose of iph5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

study d6770c00001 is a phase 1, first-in-human, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, and immunogenicity of iph5201 in adult subjects with advanced solid tumors, when administered as monotherapy or in combination with durvalumab ± oleclumab.

Eligibility criteria:
inclusion criteria: * adult subjects; age ≥ 18 years * eastern cooperative oncology group (ecog) performance status of 0 or 1. * subjects diagnosed with advanced solid tumors. * for part 1 and part 2 (iph5201 in monotherapy or combined with durvalumab):subjects must be refractory to standard therapy or for which no standard therapy exists. * for part 3 (iph5201 combined with durvalumab and oleclumab): subjects must have received and radiologically progressed on 1 prior line of systemic therapy for metastatic pancreatic ductal adenocarcinoma. * subjects must have at least 1 measurable lesion according to recist v1.1. * subjects must provide tumor specimens . exclusion criteria: * receipt of any conventional or investigational anticancer therapy (anti-ctla-4, anti-pd-1, anti-pd-l1 antibodies) within 21 days of the planned first dose. * receipt of agents targeting cd73, cd39, or adenosine receptors. * concurrent enrollment in another therapeutic clinical study. * any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent. * no toxicity leading to permanent discontinuation of prior io therapy * subjects must not have required the use of additional immunosuppression other than corticosteroids * active or prior documented autoimmune or inflammatory disorders within the past 5 years * cardiac and vascular criteria: * presence of myocardial infarction or unstable angina , or stroke, within 6 months. * congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension * history of severe hypertension * history of any grade of blood clot within 6 months * active infection, including tuberculosis; hepatitis b virus (hbv); hepatitis c virus (hcv); or human immunodeficiency virus (hiv) * uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study. * other invasive malignancy within 2 years. * major surgery within 28 days prior to first dose * female subjects who are pregnant or breast feeding
virtual reality pain study

Conditions: Hospitalized Patients 18 Years of Age or Older With Pain

Summary: investigating pain in hospitalized patients in two groups: virtual reality usage group vs standard of care

patients will be randomized to either the virtual reality group or the standard of care group. the virtual reality group will use the device over two days. both groups will answer questionnaires regarding their pain and anxiety. medical records will be used to look at pain medication usage in both groups.

Eligibility criteria:
inclusion criteria: * • patients at least 18 years of age, * reported pain in last 24 hours ≥ 3 on the numerical rating scales (nrs), * patients undergoing surgery, * expected hospital length of stay of at least 48 hours, * english fluency, * willing to comply with study procedures. * hx opioid use exclusion criteria: * • gross cognitive impairment that would interfere with the ability to consent or complete study procedures * current or prior diagnosis of epilepsy, seizure disorder, dementia, or migraines, * hypersensitivity to flashing light or motion, * history of motion sickness or cyber sickness, * medical condition predisposing to or current nausea, vomiting or dizziness, * stereoscopic vision or severe hearing impairment, * injury to eyes, face or neck that impedes comfortable use of virtual reality, * cancer related pain, * phq-9 screen indicating suicidal ideation, patients will be referred to appropriate clinical intervention (see suicide protocol) * currently pregnant, * current or recent completion of participation in any interventional pain study (with in past 2 months) * substance abuse (alcohol or illegal drugs): alcohol- niaaa definition of heavy drinking as more than 4 drinks on any day or more than 14 drinks per week for men, more than 3 drinks on any day or more than 7 drinks per week for women. any illegal drugs including marijuana